The future is now: model-based clinical trial design for Alzheimer's disease.
about
Modeling-Enabled Systems Nutritional ImmunologyThe impact of the Alzheimer's Disease Neuroimaging Initiative 2: What role do public-private partnerships have in pushing the boundaries of clinical and basic science research on Alzheimer's disease?Drug development in Alzheimer's disease: the path to 2025Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker TeamPrecompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson's DiseaseThe Traumatic Brain Injury Endpoints Development (TED) Initiative: Progress on a Public-Private Regulatory Collaboration to Accelerate Diagnosis and Treatment of Traumatic Brain Injury.A model qualification method for mechanistic physiological QSP models to support model-informed drug development.A review of disease progression models of Parkinson's disease and applications in clinical trialsPenalized nonlinear mixed effects model to identify biomarkers that predict disease progression.Disease Progression Modeling: Key Concepts and Recent DevelopmentsAccelerating drug development for Alzheimer's disease through the use of data standardsFunctional amyloids: interrelationship with other amyloids and therapeutic assessment to treat neurodegenerative diseases.Mild Cognitive Impairment.Global Standards to Expedite Learning From Medical Research Data.The Role of Public-Private Partnerships in Catalyzing the Critical Path.Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab.
P2860
Q26766623-0D76EB65-07D7-41FB-97A7-FCFDAC961CD7Q26801634-30A0AE12-D06E-4347-82A7-A30D9D6C4328Q27007748-864FCC53-7CDA-415F-A912-FAE544CCE143Q28595520-CB7B1443-500F-4843-9BB0-D209CDF8732DQ28601965-C380439C-0E80-477A-83E2-FD11E71AC706Q36330425-E52865B7-C930-4594-B7A3-41F0AE3B3AA1Q36600060-81F3B000-FE0C-45D8-82DB-32AF0F4D1A24Q37062838-1B4B11CF-3DBC-4BF3-B79E-F2467E958677Q38759319-01C7B343-8B1A-47F9-AD7C-FBF6172E122DQ41639443-274FF16A-695C-4046-AB8F-911E460D1A95Q42655623-49E3087A-01B2-4C13-A950-BC0C22F5E514Q47404503-7A5BC575-BACA-4D79-94E4-135720B8CC0AQ51305325-A8407BE6-BC4F-4301-B1C8-7BF53DCA37FAQ52561888-15225457-D854-4957-B978-3DAE7DDA1DB6Q53707802-DD13C758-C202-4996-8902-54D4E74FE173Q54942565-04EFEF2E-3B6E-4DC4-88EF-6AF55C406B06
P2860
The future is now: model-based clinical trial design for Alzheimer's disease.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
The future is now: model-based clinical trial design for Alzheimer's disease.
@en
type
label
The future is now: model-based clinical trial design for Alzheimer's disease.
@en
prefLabel
The future is now: model-based clinical trial design for Alzheimer's disease.
@en
P2093
P2860
P356
P1476
The future is now: model-based clinical trial design for Alzheimer's disease
@en
P2093
Alzheimer's Disease Neuroimaging Initiative
B Corrigan
Coalition Against Major Diseases
D Polhamus
D Stephenson
J A Rogers
P2860
P304
P356
10.1002/CPT.16
P407
P577
2014-12-27T00:00:00Z